FDA postmarket cybersecurity for pacemakers, ICDs, monitors, and remote follow-up - SBOM monitoring, CVD program, and reviewer-ready PMA Annual Reports.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Postmarket cybersecurity for cardiovascular devices is the canonical use case in FDA's postmarket guidance and AAMI TIR97 - long lifetimes, large fleets, multi-element architectures, and a public history of disclosed vulnerabilities. Our postmarket program for this segment covers the four things reviewers and CISA both expect to see: SBOM monitoring, a Coordinated Vulnerability Disclosure (CVD) program, postmarket threat-landscape surveillance, and a documented update / remediation pathway for fielded devices.
We operate ongoing SBOM monitoring across implant, programmer, home monitor, and cloud against NVD/OSV/GHSA, with auto-generated VEX drafts your team triages - the day-one VEX is not enough for a 10-year fleet. We stand up or operate a CVD program aligned to ISO/IEC 29147 and 30111, with clear intake, triage, and disclosure timelines, and integration with FDA and CISA disclosure channels. We track postmarket cyber threat intelligence specific to your device class (cardiac CIEDs are a high-attention surface for security researchers) and surface what matters. And we maintain the documented update pathway - which devices in the field can take which patches, who's authorized, and how that's evidenced in PMA Annual Reports and Section 524B postmarket submissions. We've operated this kind of program for cardiac OEMs through public CVE disclosures.
The cardiovascular system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this fda postmarket cybersecurity.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Four phases, fixed fee, scoped to cardiovascular architecture from kickoff onward.
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
eSTAR-format report with findings, CVSS, remediation, and retests until every finding with uncontrolled risk is closed.
The patterns we hit in this segment, this service, again and again.
Submitted SBOM is a snapshot. New high-severity CVEs land with no exploitability determination; reviewer asks for current state.
Researcher contact is a generic security@ alias with no SLA. Disclosure handled ad-hoc; no ISO/IEC 29147 alignment.
Newer generation supports OTA; older deployed generation does not. No documented strategy for the older fleet's CVE response.
No structured intel intake for the segment. Public researcher disclosures discovered late.
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about in this segment - and what our scope is built to cover.
"Blue Goat Cyber helped us navigate our first end-to-end cybersecurity testing for our wearable medical device. Their communication was excellent, their timeline exceeded expectations, and their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
The same deliverables the parent FDA Postmarket Cybersecurity service ships with - tuned to your cardiovascular architecture.
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
The Cardiovascular baseline, plus the call-outs that matter for fda postmarket cybersecurity in this segment.
Cardiac fleets are explicitly the use case these documents anticipate. Reviewers expect direct alignment.
CVD program structure reviewers and CISA both reference. We align the program to these as standard.
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
The questions buyers in this segment actually ask before scoping a fda postmarket cybersecurity engagement.
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
PreSTAR vs eSTAR explained: PreSTAR is the voluntary FDA template for Q-Submissions, eSTAR is required for 510(k) and De Novo. How cybersecurity carries across.
Medical device cybersecurity at each study stage: rodent, large animal, primate, and human trials, and what the FDA expects before your IDE and marketing submission.
What a medical device security advisor does after FDA clearance: keeping the threat model and SBOM current, rating vulnerabilities, and answering hospitals.
Teams in this segment commonly bundle these alongside fda postmarket cybersecurity.
A 30-minute call with a senior engineer who has done this in cardiovascular before - not a sales rep.
